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Background
Recent findings suggest that a specific deletion of Dicer1 in mesenchymal stromal cells-derived
osteoprogenitors triggers several features of myelodysplastic syndrome in a murine model. Our
aim was to analyze DICER1 and DROSHA gene and protein expression in mesenchymal stromal
cells (the osteoblastic progenitors) obtained from bone marrow of myelodysplastic syndrome
patients, in addition to microRNA expression profile and other target genes such as SBDS, a
DICER1-related gene that promotes bone marrow dysfunction and myelodysplasia when
repressed in a murine model. 
Design and Methods
Mesenchymal stromal cells from 33 bone marrow samples were evaluated. DICER, DROSHA and
SBDS gene expression levels were assessed by real-time PCR and protein expression by Western
blot. MicroRNA expresion profile was analyzed by commercial low-density arrays and some of
these results were confirmed by individual real-time PCR. 
Results
Mesenchymal stromal cells from myelodysplastic syndrome patients showed lower DICER1
(0.65±0.08 vs. 1.91±0.57; P=0.011) and DROSHA (0.62±0.06 vs. 1.38±0.29; P=0.009) gene expres-
sion levels, two relevant endonucleases associated to microRNA biogenesis, in comparison to nor-
mal myelodysplastic syndrome. These findings were confirmed at protein levels by Western blot.
Strikingly, no differences were observed between paired mononuclear cells from myelodysplastic
syndrome and controls. In addition, mesenchymal stromal cells from myelodysplastic syndrome
patients showed significant lower SBDS (0.63±0.06 vs. 1.15±0.28; P=0.021) gene expression lev-
els than mesenchymal stromal cells from healthy controls. Furthermore, mesenchymal stromal
cells from myelodysplastic syndrome patients showed an underlying microRNA repression com-
pared to healthy controls. Real-time PCR approach confirmed that mir-155, miR-181a and miR-
222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome
patients. 
Conclusions
This is the first description of an impaired microRNA biogenesis in human mesenchymal stro-
mal cells from myelodysplastic syndrome patients, where DICER1 and DROSHA gene and pro-
tein downregulation correlated to a gene and microRNA abnormal expression profile, validat-
ing the animal model results previously described. 
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Introduction
In recent years, several studies have reported that the BM
microenvironment in MDS shows qualitative and function-
al abnormalities in vitro,1,2 suggesting a potential role for
these cells in inefficient or malignant hematopoiesis.3
However, the study design of most these studies was rather
complex structure and results are controversial.
Mesenchymal stromal cells (MSC) are a small, non-
hematopoietic, BM microenvironment cell population.
Considered to be the osteoblastic progenitors, they are also
enrolled as key components into the hematopoietic
microenvironment.2 Some authors2,4-7 have shown that
MSC display several morphological, immunophenotypic
and genetic alterations in these syndromes. In a previous
study,8 we observed that MSC from MDS patients show
several genomic alterations with their consequent loss of
function. However, the effect of these abnormal features on
the impaired development of HSC remains unclear.
More recently, Raaijmakers et al.9 reported that deletion
of Dicer1, an RNase III enzyme involved in microRNA bio-
genesis, in MSC-derived osteoprogenitors resulted in
peripheral blood cytopenias, myelodysplasia and secondary
leukemia in a murine model, providing evidence that spe-
cific molecular alterations in the microenvironment could
result in clonal hematopoiesis. Furthermore, they observed
a reduced expression of SBDS, the gene mutated in
Schwachman–Bodian–Diamond syndrome, related to bone
marrow failure and with high risk of developing leukemia.9
The aim of the present study was to analyze DICER1 and
DROSHA (another RNA III endonuclease) gene and protein
expression in MSC (the osteoblastic progenitors) obtained
from BM of MDS patients, as well as the microRNAs
expression along with some target genes such as SBDS,
TP53, PTEN, MYC and SDF1, showing that MSC from
MDS patients showed a reduced expression of DICER1,
DROSHA and SBDS when compared to normal MSC. 
Design and Methods
Patients and control samples
For DICER1 and DROSHA analysis, 33 BM samples from de novo
and untreated MDS, (8 5q- syndrome, 5 RA, 5 RARS, 8 RCMD, 4
RAEB, 2 MDS-U and 1 hypocellular MDS) were included. MDS
diagnosis was based on the 2008 WHO criteria.10 Male to female
ratio was 14:19 and mean age was 73.9 years (range 53-87). Non-
malignant BM samples were obtained from 25 healthy donors
(HD), 12 men and 13 women, with a mean age of 75.6 years
(range, 55-87). Additionally, paired mononuclear cells (MNC) from
11 MDS and 8 HD were obtained. The study was approved by the
institutional review board at each participating center and all
patients gave written informed consent to use biological samples
and clinical data.
Isolation and expansion of mesenchymal cells
MSC were isolated and characterized by flow cytometry from
BM samples of patients and healthy controls as previously
described.8,11 In addition, osteogenic, adipogenic and chondrogenic
differentiation was demonstrated following standard procedures
described elsewhere.8,12
Gene expression analysis 
Total RNA was obtained from either MSC or MNC with
Trizol (Invitrogen) and subsequent reverse transcription was car-
ried out using the High Capacity kit (Applied Biosystems, Foster
City, CA, USA). Gene expression of DICER1, DROSHA, SBDS,
TP53, SDF1, MYC, PTEN and GAPDH (as control gene) was
quantified by using commercial TaqMan® Gene Expression
Assays and the Step One Plus Real-Time PCR System  (Applied
Biosystems). Relative quantification was calculated using the 2-
ΔΔCt values where:
ΔCt = CtGene - CtGAPDH and ΔΔCt = mean(ΔCtMDS) -
mean(ΔCtHealthyDonors). 
Values were expressed as mean ± standard error. Differences
between MDS and controls were analyzed using non-parametric
Mann-Whitney U test and Wilcoxon's test for paired samples.
microRNA expression analysis
RNA (350-1000 ng) of MSC from 21 low-risk MDS and 11 HD
were retrotranscribed with Megaplex™ RT Primers primer pool
(Applied Biosystems). We loaded 384-well microfluidic cards
(TaqMan® MicroRNA Array A) with retro-transcription product
and PCR runs were performed on a 7900HT Fast Real-time PCR
system (Applied Biosystems). 
MicroRNA expression data were processed within the R statis-
tical computing environment (version 2.10.0), using ΔΔCt stan-
dard procedures from the HTqPCR package.13 The raw Ct values
were normalized using the array endogenous control features by
ΔCtmiRNA = CtmiRNA – mean(CtMammU6). MicroRNA differential expres-
sion was tested based on the ΔΔCt values where:
ΔΔCtmiRNA = mean(ΔCtMDS) - mean(ΔCtHealthyDonors). 
The Benjamini-Holm method was applied for multiple testing
corrections of raw P values extracted from the t-test statistic. Also
the Log Transformed Relative Quantifications (2-ΔΔCt) for each
microRNA, the so called Fold Changes (FC), were calculated.
To confirm microRNA expression findings by low-density
arrays, we performed individual quantitative PCR for the follow-
ing microRNAs: Hsa-mir-26b, Hsa-mir-34c-5p, Hsa-mir-125a-5p,
Hsa-mir-129-3p, Hsa-mir-146a, Hsa-mir-150, Hsa-mir-153, Hsa-
mir-155, Hsa-mir-181a and Hsa-mir-222. RNA samples used in
low-density arrays from 19 MDS patients (6 5q-, 1 RA, 1 RARS,
8 RCMD, 2 MDS-U and 1 hypocellular MDS) and 8 HD were
retrotranscripted according to TaqMan® MicroRNA Reverse
Transcripcion Kit (Applied Biosystems). Fold-Differences were
calculated using the same ΔΔCt method described previously. 
Data relating to the targeting of our miRNAs over genes
were collected from the miRNA Validated Target repository,
available at the miRWalk database (web link http://www.ma.uni-
heidelberg.de/apps/zmf/mirwalk/mirnatargetpub.html).
For a better biological understanding of the expression results,
we collected the genes reported as validated targets of our rele-
vant microRNAs from the miRWalk database (data released
March 2011).14 Furthermore, their gene functional pathways were
analyzed using the Ingenuity Pathways Analysis software (IPA).
Western blot analysis
Whole cell lysates were obtained from MSC. Samples (30 µg)
were loaded on a 6% and 10% SDS-PAGE gel for antibody
SBDS. Used primary antibodies were: mouse α-DICER1 (1:500;
ab14601; Abcam Inc.), rabbit α-DROSHA (1:2000; ab12286;
Abcam Inc.), goat α-SBDS (1:200, sc-49257; Santa Cruz
Biotechnology, Inc.)  and rabbit α-calnexin (1:50000; SPA-860;
StressGen) as loading control. Membranes were incubated with
either anti-mouse or anti-rabbit IgG horseradish peroxidase-con-
jugated secondary antibody (Amersham Biosciences). Specific
bands were visualized by using ECL Western Blotting Detection
Reagents (Amersham Biosciences).
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Results 
DICER1 and DROSHA
Gene expression analysis of DICER1 and DROSHA by
real-time PCR in MSC from MDS patients showed signif-
icantly lower DICER1 (0.65±0.08 vs. 1.91±0.57; P=0.011)
and DROSHA (0.62±0.06 vs. 1.38±0.29; P=0.009) (Figure
1A) gene expression levels in MSCs from MDS patients
when compared to healthy donors (HD-MSC). By con-
trast, no difference in DICER1 (1.35±0.29 vs. 1.19±0.27;
P=0.9) or DROSHA (1.48±0.10 vs. 1.12±0.22; P=0.09)
gene expression was observed between MNC from MDS
and HD (Figure 1B). These results were independent of
leukocyte differential counts in original samples. When
MSC were compared with MNC from paired MDS
patients (n=11) a significantly lower expression of both
DICER1 (0.19±0.03 vs. 1.36±0.34; P=0.003) and DROSHA
(0.87±0.11 vs. 1.48±0.12; P=0.008) were observed in stro-
mal cells (Figure 1C). When MSC and MNC from healthy
donors (n=8) were compared, no differences were
observed in either DICER1 (MNC 1.19±0.77 vs. MSC
1.91±2.84; P=0.4) or DROSHA (MNC 1.12±0.61 vs. MSC
1.39±1.45; P=0.6) gene expression levels. Finally, we
assessed the association between RNA levels of both
markers in MSC, resulting in a strong correlation between
DICER and DROSHA gene expression levels (Spearman’s
Rho correlation=0.832, P<0.001, Figure 1D).
Because 5q- syndrome patients are a separate and well-
defined entity among MDS, we compared DICER1 and
DROSHA expression between 5q- syndrome and other
MDS but no statistical differences were observed
(P>0.05). 
In order to confirm quantitative PCR data, Western blot
analysis was performed in MSC from MDS and com-
pared with controls. MSC from MDS patients showed a
lower protein expression of DICER1 and DROSHA, sup-
porting gene expression results (Figure 1A).
SBDS expression
Since Dicer1-deleted murine osteoprogenitors showed
lower Sbds expression levels, and deletion of Sbds in
mouse osteoprogenitors induced bone marrow dysfunc-
tion with myelodysplasia,9 we decided to quantify SBDS
in human MSC from MDS. SBDS was significantly down-
expressed by real-time PCR analysis in MSC from MDS
patients when compared with MSC from healthy donors
(0.63±0.06 vs. 1.15±0.28; P=0.021) (Figure 2).
According to Western blot, different SBDS protein levels
were observed among MSC from MDS patients (Figure
2B). Although MSC from non 5q- MDS groups (5 RCMD,
2 RAEB and 1 RARS) showed no clear differences com-
pared to healthy MSC, we observed a reduced SBDS
expression in 3 out of 4 MSC from 5q- in comparison to
normal MSC, but the small number of evaluated samples
C. Santamaría et al.


























































































HD-MSC MDS-MSC HD-MNC MDS-MNC HD-MNC MDS-MNC
Spearman’s Rho correlation=0.832
P<0.001
































Figure 1. DICER1 and DROSHA expression in myelodysplastic syndrome patients (MDS) and healthy donors (HD). (A) Analysis in mesenchy-
mal stromal cells (MSC) by quantitative PCR and Western blot. (B) Analysis in mononuclear cells (MNC) by quantitative PCR. (C)  DICER1
and DROSHA comparison between paired MSC and MNC from MDS patients by quantitative PCR. (D) Relationship between DICER and
DROSHA in MSCs from MDS patients. Outlier’s values in the boxplot are represented by a circle or asterisk (extreme outliers)
means results are not conclusive. Furthermore, no correla-
tion between gene and protein expression were observed
in those MDS cases with paired samples (n=8; data not
shown).
MicroRNA expression analysis   
When differential expression analysis of microRNA
quantitative-PCR arrays was performed, an underlying
microRNA repression in MDS samples compared to
healthy controls was observed (Figure 3). Although the
multiple testing adjusted P values did not reach statistical
significance, we found 370 out of all 380 tested
microRNAs (97%) with a decreased expression level in
MDS cells versus control cells (averaged FC=-0.42); 159 out
of those ranked microRNAs showed a raw P value of less
than 0.05 (averaged FC=-0.71, minFC=-0.31, maxFC=-
1.28; Online Supplementary Table S1).
Because DICER1 and DROSHA were down-expressed,
and a tendency towards lower expression in miRNAs was
observed, an analysis of some miRNAs involved in
hematopoiesis regulation was performed by real-time
PCR. hsa-miR-155 (P=0.015) and hsa-miR-181a (P=0.05)
were significantly down-expressed in MSC from MDS
patients, whereas a trend towards lower hsa-miR-222
expression in MSC from MDS was also observed
(P=0.082; Table 1). Those same microRNA were shortlist-
ed among the 159 down-regulated miRNAs into the
qPCR-array data with the corresponding FC values: hsa-
miR-222 =-0.406; hsa-miR-181a =-0.597; hsa-miR-155 =-
0.464 (Online Supplementary Figure S1).
DICER1 and DROSHA have been reported to be targets
of these three miRNAs. In fact, 32 of 159 down-regulated
microRNAs presented reported interactions with DICER1
(Online Supplementary Table S2). Furthermore, many
important genes involved in hematopoiesis were found as
validated targets of the three down-expressed
microRNAs. According to Ingenuity Pathways Analysis
software, the main functional pathways in which they are
involved are: cell death, cell growth and proliferation, cell
cycle, cellular development, DNA replication and repair,
cancer, hematologic system development and function,
gene expression, cellular function and maintenance. 
Furthermore, four additional target genes of down-
expressed microRNA with relevant role in MDS pathogen-
esis (MYC,15 PTEN,16 SDF117 and TP5318) were also evaluat-
ed. Of these selected genes, only SDF1 showed a signifi-
cant lower expression in MSCs from MDS patients com-
pared to MSC from healthy donors (P=0.026; Table 2).
Discussion
In a previous study8 we reported that MSC from MDS
patients can show genomic changes with functional
impairment, suggesting a possible role in MDS patho-
physiology. Here, we describe for the first time how MSC
from MDS patients show a low expression of DICER1,
DROSHA and SBDS, as well as a global downregulation
of microRNA expression.
Raaijmakers et al.9 recently published a pivotal paper in
which they reported that specific deletion of Dicer1 in
murine MSC-derived osteoprogenitors triggered blood
cytopenias, high apoptosis rate, myelodysplasia and sub-
sequent AML development. Based on these findings, we
analyzed DICER1 and DROSHA, two relevant RNA
endonucleases, in MSC from MDS patients, and we
observed a lower gene  and protein  expression levels of
both of them when compared to healthy donors MSC.
This low expression in MSC was also observed when
paired mononuclear cell-MSC from MDS patients were
evaluated. By contrast, no differences were observed
between mononuclear cells from MDS and healthy
donors or paired mononuclear cells-MSC from healthy
donors. Therefore, our results show that DICER1 and
DROSHA down-regulation is exclusively observed in
MSC from MDS, confirming previous findings in murine
models. 
One of the most striking features in the study per-
formed by Raaijmakers et al. was the reduced expression
of Sbds, the gene mutated in Schwachman-Bodian-
Diamond syndrome, a human entity characterized by BM
failure and tendency to develop AML, in MSC from the
murine MDS model.9 In order to verify whether this gene
could also be altered in human MDS we compared SBDS
expression in MSC from MDS and healthy donors, show-
ing that SBDS gene expression was down-expressed in the
former group. But at a protein level, only 5q- syndrome
samples showed a trend towards lower SBDS expression,
suggesting that, at least in 5q- cases, SBDS downexpres-
sion in MSC could play a potential role in MDS pathogen-
esis. 
DICER1 and DROSHA are involved in microRNA bio-
DICER-DROSHA and microRNA in MSC from MDS
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Figure 2. SBDS gene expression in mes-
enchymal stromal cells (MSC) from
myelodysplastic syndrome patients (MDS)
and healthy donors (HD). Control MSC
from healthy donors are indicated with a C
letter (3 samples in upper panel and 1 in
lower panel). MSC from MDS samples are
detailed as follows: 5q- syndrome (lines 2,
3, 6 and 8), RARS (lines 4, 5, 7, 11 and
12),  RAEB1 (line 1), RAEB2 (line 10), and
RARS (line 9).
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Figure 3. MicroRNA expression pattern by TaqMan® MicroRNA Arrays. A barplot representing the most 200 down-regulated MicroRNA is
shown. Bars represent individual microRNA Ct mean values in MDS samples (in yellow) versus Ct mean values in HD samples (in green).
Mean expression value from MDS and control samples for each evaluated microRNA are included in the Online Supplementary Table S1.
genesis, small single- stranded RNAs that function as
guide molecules in post-transcriptional gene regulation,
covering a broad spectrum of processes, including apopto-
sis and hematopoiesis.19 Very few studies have evaluated
DICER1 or DROSHA activity in MSC and they focused on
their role in differentiation of MSCs.20,21 Thus, to gain
insight into the biological effects of low DICER1 and
DROSHA expression in MSC-MDS, we further analyzed
mature microRNA expression profile, showing a trend
towards global downexpression in MDS-MSC when com-
pared with normal MSC. These results could be associat-
ed with the inherent biological diversity among MDS sub-
types. Among the recruited validated target genes of the
strongest down-regulated miRNAs we found a strikingly
high representation of the DICER1 gene. All these features
could also suggest the action of a compensatory mecha-
nism to improve miRNA biogenesis. One additional
explanation could be alternative (non-canonical) DICER
and DROSHA-independent mechanisms of miRNA bio-
genesis that have been recently described;22-24 however,
these were not evaluated in the present study. Together,
all these findings (DICER, DROSHA and microRNA dis-
regulation) suggest that the canonical machinery regulat-
ing microRNA biogenesis in MSC from MDS patients is
impaired.
We wanted to evaluate the potential role of these dereg-
ulated microRNA in the MDS pathology. We were able to
observe that 3 out of 10 miRNAs (miRNA-155, miRNA-
181a and miRNA-222) showed lower gene expression in
MSC from MDS patients when compared with those
from healthy donors. Of note, the 3 microRNA previous-
ly referred to have relevant roles in normal and malignant
hematopoietic processes.19,25,26 The potential effects of
these microRNA deregulation on hematopoietic stem cells
remain unclear, but it has recently been shown that MSC
may secrete microRNA as well as other nucleic acids and
proteins, into microvesicles, suggesting a novel mecha-
nism of intercelular communication and regulation.27,28
It must also be stressed that DICER1 and DROSHA are
target genes of these three miRNAs, so it could be hypoth-
esized that complex mechanisms involving DICER1-
DROSHA-microRNAs could be observed in MSC-MDS as
compensatory mechanisms. Furthermore, many target
genes of these miRNAs are involved in molecular path-
ways related to hematopoiesis.19 In this context MYC,
PTEN, SDF1 and TP53 are target genes of down-regulated
miRNAs (miR-155 and miR-181a) which are involved in
the control and regulation of hematopoiesis.15-18 SDF1, that
is down-expressed in MSC from MDS patients, is a mole-
cule involved in migration and attachment of HSC to its
niche. It has been proposed that the SDF1-CXCR4 axis is
impaired in MDS patients.17 The rationale for this gene
downexpression associated with a global down-regulated
microRNA expression remains elusive. However, it is
important to note that micro-RNAs can act not only as
repressors but also as enhancers of gene expression,29 sug-
gesting that the regulatory mechanisms are very complex.
In summary, we describe for the first time that MSC
from MDS patients show low gene and protein expression
of DICER1 and DROSHA which are involved in the
microRNA biogenesis, as well as their target gene SBDS,
confirming recent findings in a murine model.
Furthermore, these cells showed several deregulated
microRNAs, mostly down-regulated. Together, these find-
ings suggest that MSC might be involved in MDS patho-
genesis. 
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Table 1. Comparison of microRNA expression (ΔΔCt method) by real-
time PCR between mesenchymal stromal cells (MSC) from healthy
donors (HD) and MDS patients.
miRNA MSC-HD MSC-MDS P
median (range) median (range)
155 0.81(0.40-2.04) 0.33(0.07-42.99) 0.015
181a 1.98(1.19-4.17) 1.0(0.15-3.25) 0.05
222 50.11(38-90) 35.26(3.92-133.58) 0.082
150 0.002(0.0006-0.13) 0.005(0.001-0.1) 0.19
146a 0.13(0.03-2.81) 0.08(0.005-9.95) 0.408
125a-5p 1.20(0.59-1.40) 1.06(.42-11.94) 0.462
129-3p 1.97(0.37-7.46) 1.93(0.68-6.89) 0.606
153 1.29(0.11-2.76) 0.44(0.00-7.97) 0.606
34c-5p 1.07(0.37-2.03) 0.90 (0.14-16.57) 0.897
26b 1.02(0.55-1.32) 0.91(0.33-5.89) 0.806
Table 2. Comparison of gene expression of selected target genes of
down-regulated microRNA between mesenchymal stromal cells (MSC)
from MDS patients (n=14) and healthy donors (HD; n=5).
Target gene MSC-HD MSC-MDS P
median (range) median (range)
SDF1 0.86 (0.53-2.66) 0.49 (0.05-1.22) 0.026
TP53 0.90 (0.60-2.61) 1.31 (0.28-4.26) 0.414
PTEN 0.89 (0.21-14.34) 1.16 (0.04-14.99) 0.733
MYC 1.74 (0.09-2.62) 1.28 (0.71-4.41) 0.882
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